摘要
目的:分析平阳霉素瘤内注射治疗儿童腮腺血管瘤的临床疗效。方法:选取我院2014年5月—2017年5月收治的38例腮腺血管瘤患儿为本次实验研究对象,按照临床治疗方案不同将所有患儿均分为实验组与对照组,对照组19例患儿给予常规手术治疗,实验组19例患儿给予平阳霉素瘤内注射治疗,比较两组患儿临床治疗效果。结果:实验组患儿治愈率为46.1%,对照组患儿治愈率为26.3%;实验组患儿并发症发生率为15.8%,对照组患儿并发症发生率为42.1%;实验组患儿治疗后面神经Ⅳ级-Ⅴ级例数明显多于对照组;实验组患儿及家属对临床治疗满意度明显优于对照组(89.5%vs63.2%);两组患儿各项数据差异明显均具有统计学意义(P<0.05)。结论:腮腺血管瘤儿童给予平阳霉素瘤内注射治疗可有效促进患儿血管瘤消退,提升患儿颜面外观,并发症发生率低。
Objective： To analyze the clinical effect of Pingyangmycin on intratumoral injection of children with parotid hemangioma. Methods： From May 2014 to May 2017, 38 children with parotid hemangioma were enrolled in this study. All the children were divided into experimental group and control group according to different clinical treatment regimen. In the control group, 19 cases Children were given routine surgical treatment, the experimental group of 19 cases of children given Pingyangmycin intratumoral injection treatment, compared the two groups of children with clinical treatment. Results： The cure rate was 46.1% in the experimental group and 26.3% in the control group. The complication rate was 15.8% in the experimental group and 42.1% in the control group. The cases of face nerve Ⅳ-Ⅴ were higher in the experimental group than the control group. The satisfaction degree of patients was better in the experimental group than the control group（89.5% vs 63.2%）, with statistical significance（P〈0.05）. Conclusion： Intratumoral injection of Pingyangmycin in children with parotid hemangioma can effectively promote hematoma regression and improve facial appearance and complication rate.
出处
《药品评价》
CAS
2018年第2期46-49,共4页
Drug Evaluation
关键词
平阳霉素瘤内注射治疗
儿童腮腺血管瘤
临床疗效
Pingyangmycin Intratumoral Injection
Children's Parotid Hemangioma
Clinical Efficacy
